Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
Roche (RHHBY) announced the CE certification of the new cobas 6800/8800 systems 2.0. The update significantly enhances the efficiency of laboratories by optimizing resources, reducing downtime ...
The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers ... of SARS-CoV-2 assays on the cobas 6800/8800 systems since the end of the pandemic.
Roche Diagnostics CEO Matt Sause said: “Rapid molecular point-of-care testing ... CE mark certification for its updated cobas 6800/8800 systems 2.0, enhancing laboratory and testing capabilities.
Basel, 22 January 2025 - Roche (SIX: RO, ROG ... with commercialisation under CE mark expected to follow shortly. “Rapid molecular point-of-care testing can revolutionise the clinical management ...
Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...
The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based settings for patients at risk for chlamydia, gonorrhea, and Mycoplasma ...
More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15-49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to ...
said Matt Sause, CEO Roche Diagnostics. The cobas liat system utilises gold-standard PCR technology to provide results in 20 minutes or less. The cobas liat assays are CLIA waived*, enabling ...